We have previously shown that a novel therapeutic for treating sepsis (PKCδ TAT inhibitory peptide) similarly reduces neutrophil migration and adhesion in both our microphysiological system using primary human cells and in an animal model of sepsis (14, 15). The gene discussed is PRKCD; the disease is Sepsis.